Booth Andrew 4

What Happened

• Andrew Booth, Chief Financial Officer of AbCellera Biologics (ABCL), purchased 42,600 shares in an open-market/private purchase on 2026-02-27.
• Price: $3.42 per share; Total value: $145,692.
• This was a purchase (insider buying). Insider buys are often viewed as a more informative signal than sales, though the filing does not disclose motivation.

Key Details

• Transaction date: 2026-02-27
• Transaction type/code: Open-market/private purchase (P)
• Price per share: $3.42; Shares acquired: 42,600; Total cost: $145,692
• Shares owned after transaction: Not specified in the filing
• Footnotes/plan details: No 10b5-1 plan, tax withholding, or other special footnotes disclosed in the reported transaction
• Filing timeliness: Report filed with the SEC on 2026-02-27 (same day as the reported transaction)

Context

• This report reflects a straight purchase of common stock (no option exercise, award, or gift). Purchases by executives can indicate confidence but do not guarantee future performance.